Deep-Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non–Small Cell Lung Cancer: A Multimodal Approach (RADAR CARE Study) Within 126 QPOP cases, 105 (52 B-NHL and 53 NK/T-NHL) ...
Guidelines advocate molecular profiling in the evaluation of advanced non–small-cell lung cancer (NSCLC) and support the use of plasma circulating tumor DNA (ctDNA)-based profiling for patients with ...
Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has demonstrated that it can predict the outcome of Phase II to Phase III ...
SOUTH SAN FRANCISCO, Calif., September 24, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a ...
Because transmural healing (TH) could be the best therapeutic target in Crohn's disease (CD), we aimed to build and validate a score to assess TH and transmural response (TR), and to confirm their ...
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that EsoGuard ...
ATLANTA--(BUSINESS WIRE)--Cotiviti, a leader in data-driven healthcare solutions, is expanding its Clinical Chart Validation (CCV) solution and Prospective Accuracy claim review offerings with a new ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback